查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930113

流感治療藥物市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察，2026-2034 年

Influenza Medication Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 145 Pages | 商品交期: 請詢問到貨日

價格

流感治療藥物市場成長驅動因素

全球流感治療藥物市場在控制世界上最廣泛傳播且最具傳染性的傳染病之一—流感方面發揮著至關重要的作用。由於病毒株的不斷演變、季節性流行以及老年人、孕婦和免疫功能低下者等高危險群的存在，流感仍然是一項嚴峻的公共衛生挑戰。公眾意識的提高、診斷技術的進步以及先進抗病毒療法的出現是塑造市場格局的關鍵因素。

市場規模及預測

根據 Fortune Business Insights 的數據，2025 年全球流感治療市場規模為 9.6 億美元。預計到 2026 年將成長至 9.9 億美元，到 2034 年將達到 71.5 億美元，預測期內複合年增長率高達 14.25%。

這種強勁成長主要歸功於流感流行頻率的增加、病毒變異、診斷率的提高以及新一代抗病毒藥物的廣泛應用。

市場概覽

過去幾十年，全球流感流行呈現持續上升趨勢。美國每年爆發的流感疫情以及亞洲和歐洲的反覆爆發都大大促進了市場擴張。根據美國疾病管制與預防中心 (CDC) 統計，自 2019 年 10 月以來，美國已報告約 970 萬例流感病例，凸顯了流感持續帶來的沉重疾病負擔。

雖然季節性流感疫苗被廣泛使用，但由於病毒的基因變異性，疫苗並非總是完全有效，因此對有效抗病毒藥物的需求日益增長。

主要市場驅動因子

流感治療市場的主要驅動因素之一是人們對流感嚴重性和併發症的認識不斷提高。美國疾病管制與預防中心 (CDC) 和世界衛生組織 (WHO) 等政府醫療機構正在積極進行宣傳活動，以促進早期診斷和治療。

另一個主要驅動因素是旨在開發新療法的研發活動的增加。儘管患者人數不斷增長，但目前獲得美國食品藥物管理局 (FDA) 批准的流感治療藥物數量有限，造成了巨大的未滿足需求。巴洛沙韋酯（Xofluza）等藥物的上市為流感治療帶來了新的選擇，並提高了療效。

診斷技術進步的作用

快速流感診斷測試（RIDT）是市場成長的重要推手。這些測試可以檢測甲型和乙型流感抗原，並在 5 至 15 分鐘內提供結果。近期監管法規的變更將 RIDT 從 I 類醫療器械重新歸類為 II 類醫療器械，提高了其準確性，從而提高了診斷率，並促進了流感治療的更廣泛應用。

市場區隔分析

依治療方法劃分

根據治療方法，市場可細分為磷酸奧司他韋、巴洛沙韋酯和其他藥物。

由於奧司他韋磷酸酯的廣泛應用和確切療效，預計到2026年，其市場佔有率將達到57.44%，佔市場主導地位。然而，由於專利到期和仿製藥競爭，其成長速度正在放緩。

巴洛沙韋酯市場預計將以最高的複合年增長率成長，這得益於近期在美國和日本等主要市場的上市。

依流感類型劃分

依流感類型劃分，市場分為甲型流感和乙型流感。

由於甲型流感的高盛行率以及與大規模疫情的關聯，預計到2026年，甲型流感將佔75.82%的市場佔有率。乙型流感在某些流感季也會對市場成長做出貢獻。

依給藥途徑

口服給藥途徑佔市場主導地位，預計到2026年將佔95.02%的市場佔有率，這主要得益於其給藥方便以及達菲（Tamiflu）和舒氟沙星（Xofluza）等藥物的廣泛應用。

按分銷管道

醫院藥局佔最大的市場佔有率，這主要得益於診斷處方。零售藥房位居第二，而線上藥房預計將憑藉數位化發展實現最高的複合年增長率。

按地區分析

北美地區在流感治療市場中佔主導地位，2025 年市佔率達到 59.56%，預計 2026 年市場收入將達到 5.9 億美元。光是美國市場預計到 2026 年就將達到 5.5 億美元。

亞太地區預計將實現最快成長，預計到 2026 年，日本市場規模將達到 7,000 萬美元，中國達到 5,000 萬美元，印度達到 2,000 萬美元。歐洲流感活動的增加也推動了市場的穩定成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 流感流行病學概述
  • 主要地區流感疾病負擔分析
  • 新產品上市
  • 在開發產品分析
  • 仿製藥上市對流感治療市場的影響分析
  • 主要行業趨勢

第五章：全球流感治療市場分析、洞察與預測 （2021-2034）

  • 主要發現/摘要
  • 市場分析、洞察與預測 - 按療法劃分
    • 巴洛沙韋酯
    • 磷酸奧司他韋
    • 其他
  • 市場分析、洞察與預測 - 按流感類型劃分
    • 甲型流感
    • B型流感
  • 市場分析、洞察與預測 - 按給藥途徑劃分
    • 口服
    • 其他
  • 市場分析、洞察與預測 - 按分銷管道劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
    • 其他
  • 市場分析、洞察與預測 - 按區域
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美流感治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲流感治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 其他地區歐洲

第8章 亞太地區的流感治療藥市場分析，洞察與預測(2021～2034年)

  • 各國
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他的亞太地區

第9章 南美的流感治療藥市場分析，洞察與預測(2021～2034年)

  • 各國
    • 巴西
    • 墨西哥
    • 其他的南美

第10章 中東·非洲的流感治療藥市場分析，洞察與預測(2021～2034年)

  • 各國
    • GCC
    • 南非
    • 其他的中東·非洲

第11章 競爭分析

  • 主要產業趨勢
  • 全球市場佔有率分析(2025年)
  • 競爭形勢儀表板
  • 主要企業比較分析
  • 企業簡介
    • Genentech, Inc.
    • Shionogi & Co., Ltd.
    • Seqirus(CSL)
    • BIOCRYST PHARMACEUTICALS, INC.
    • GlaxoSmithKline plc
    • Lupin Limited
    • Teva Pharmaceutical Industries Ltd.
    • Zydus Pharmaceuticals, Inc.(Zydus Cadila)
    • Amneal Pharmaceuticals LLC
    • Macleods Pharmaceuticals Ltd.
    • Alvogen
    • 其他

第12章 策略性建議

Product Code: FBI101843

Growth Factors of influenza medication Market

The global influenza medication market plays a critical role in managing one of the most widespread and contagious infectious diseases worldwide. Influenza continues to pose a serious public health challenge due to its evolving viral strains, seasonal epidemics, and high-risk populations such as the elderly, pregnant women, and immunocompromised individuals. Growing awareness, improved diagnostics, and the launch of advanced antiviral therapies are key factors shaping the market landscape.

Market Size and Forecast

According to Fortune Business Insights, the global influenza medication market size was valued at USD 0.96 billion in 2025. The market is projected to grow to USD 0.99 billion in 2026 and reach USD 7.15 billion by 2034, registering a strong CAGR of 14.25% during the forecast period.

This robust growth is primarily attributed to the increasing frequency of influenza outbreaks, virus mutation, rising diagnosis rates, and growing adoption of next-generation antiviral drugs.

Market Overview

Influenza has shown a steady increase in global prevalence over the past few decades. Annual epidemics in countries such as the United States and recurring outbreaks across Asia and Europe significantly contribute to market expansion. According to the Centers for Disease Control and Prevention (CDC), an estimated 9.7 million influenza cases were reported in the U.S. since October 2019, highlighting the ongoing disease burden.

Although seasonal influenza vaccines are widely used, they are not always fully effective due to the genetic variability of the virus, increasing the need for effective antiviral medications.

Key Market Drivers

One of the primary drivers of the influenza medication market is increased awareness regarding the severity of influenza and its complications. Government and healthcare organizations such as the CDC and WHO actively conduct awareness campaigns, encouraging early diagnosis and treatment.

Another major driver is increased R&D activity aimed at developing novel therapeutics. Despite the growing patient population, only a limited number of FDA-approved influenza drugs are currently available, creating a large unmet treatment need. The launch of drugs such as Baloxavir Marboxil (Xofluza) has introduced new treatment options with improved efficacy.

Role of Diagnostic Advancements

Rapid Influenza Diagnostic Tests (RIDTs) have significantly influenced market growth. These tests detect influenza A and B antigens and deliver results within 5-15 minutes. Recent regulatory changes reclassifying RIDTs from Class I to Class II devices have improved their accuracy, leading to higher diagnosis rates and increased adoption of influenza medications.

Market Segmentation Analysis

By Treatment Type

Based on treatment, the market is segmented into oseltamivir phosphate, baloxavir marboxil, and others.

The oseltamivir phosphate segment dominated the market with a 57.44% share in 2026, driven by its widespread prescription and proven efficacy. However, growth is moderated due to patent expiration and generic competition.

The baloxavir marboxil segment is expected to grow at the highest CAGR, supported by recent launches in key markets such as the U.S. and Japan.

By Influenza Type

By influenza type, the market is segmented into influenza A and influenza B.

The influenza A segment accounted for 75.82% market share in 2026, owing to its high prevalence and association with major outbreaks. Influenza B also contributes to market growth during certain flu seasons.

By Route of Administration

The oral route dominated the market, accounting for 95.02% share in 2026, due to ease of administration and widespread use of drugs such as Tamiflu and Xofluza.

By Distribution Channel

The hospital pharmacies segment held the largest market share, supported by diagnosis-based prescriptions. Retail pharmacies ranked second, while online pharmacies are expected to witness the highest CAGR due to growing digital adoption.

Regional Analysis

North America dominated the influenza medication market with a 59.56% share in 2025 and generated USD 0.59 billion in revenue in 2026. The U.S. market alone is projected to reach USD 0.55 billion by 2026.

The Asia-Pacific region is expected to register the fastest growth, with Japan reaching USD 0.07 billion, China USD 0.05 billion, and India USD 0.02 billion by 2026. Europe is also witnessing rising influenza activity, supporting steady market growth.

Competitive Landscape

The market is led by key players such as Genentech, Inc., Shionogi & Co., Ltd., GlaxoSmithKline plc, Seqirus (CSL), and BioCryst Pharmaceuticals, Inc. The presence of generics makes the market mature and competitive, creating barriers for new entrants.

Conclusion

In conclusion, the global influenza medication market is poised for significant growth from USD 0.96 billion in 2025 to USD 7.15 billion by 2034, driven by rising influenza prevalence, improved diagnostics, strong R&D pipelines, and growing awareness initiatives. While generic competition remains a challenge, the introduction of advanced antiviral therapies and expanding healthcare access worldwide will continue to support long-term market expansion.

Segmentation By Treatment

  • Baloxavir marboxil
  • Oseltamivir phosphate
  • Others

By Influenza Type

  • Influenza A
  • Influenza B

By Route of Administration

  • Oral
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Overview of Influenza Epidemiology
  • 4.2. Analysis of Disease Burden of Influenza, By Key Regions
  • 4.3. New Product Launches
  • 4.4. Pipeline Analysis
  • 4.5. Analysis of the Impact of the Launch of Generics on the Influenza Medication Market
  • 4.6. Key Industry Developments

5. Global Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Treatment
    • 5.2.1. Baloxavir marboxil
    • 5.2.2. Oseltamivir phosphate
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Influenza Type
    • 5.3.1. Influenza A
    • 5.3.2. Influenza B
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Oral
    • 5.4.2. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
    • 5.5.4. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Treatment
    • 6.2.1. Baloxavir marboxil
    • 6.2.2. Oseltamivir phosphate
    • 6.2.3. Others
  • 6.3. Market Analysis - By Influenza Type
    • 6.3.1. Influenza A
    • 6.3.2. Influenza B
  • 6.4. Market Analysis - By Route of Administration
    • 6.4.1. Oral
    • 6.4.2. Others
  • 6.5. Market Analysis - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
    • 6.5.4. Others
  • 6.6. Market Analysis - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Treatment
    • 7.2.1. Baloxavir marboxil
    • 7.2.2. Oseltamivir phosphate
    • 7.2.3. Others
  • 7.3. Market Analysis - By Influenza Type
    • 7.3.1. Influenza A
    • 7.3.2. Influenza B
  • 7.4. Market Analysis - By Route of Administration
    • 7.4.1. Oral
    • 7.4.2. Others
  • 7.5. Market Analysis - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
    • 7.5.4. Others
  • 7.6. Market Analysis - By Country/Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Treatment
    • 8.2.1. Baloxavir marboxil
    • 8.2.2. Oseltamivir phosphate
    • 8.2.3. Others
  • 8.3. Market Analysis - By Influenza Type
    • 8.3.1. Influenza A
    • 8.3.2. Influenza B
  • 8.4. Market Analysis - By Route of Administration
    • 8.4.1. Oral
    • 8.4.2. Others
  • 8.5. Market Analysis - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
    • 8.5.4. Others
  • 8.6. Market Analysis - By Country/Sub-Region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Treatment
    • 9.2.1. Baloxavir marboxil
    • 9.2.2. Oseltamivir phosphate
    • 9.2.3. Others
  • 9.3. Market Analysis - By Influenza Type
    • 9.3.1. Influenza A
    • 9.3.2. Influenza B
  • 9.4. Market Analysis - By Route of Administration
    • 9.4.1. Oral
    • 9.4.2. Others
  • 9.5. Market Analysis - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies
    • 9.5.3. Online Pharmacies
    • 9.5.4. Others
  • 9.6. Market Analysis - By Country/Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Treatment
    • 10.2.1. Baloxavir marboxil
    • 10.2.2. Oseltamivir phosphate
    • 10.2.3. Others
  • 10.3. Market Analysis - By Influenza Type
    • 10.3.1. Influenza A
    • 10.3.2. Influenza B
  • 10.4. Market Analysis - By Route of Administration
    • 10.4.1. Oral
    • 10.4.2. Others
  • 10.5. Market Analysis - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
    • 10.5.4. Others
  • 10.6. Market Analysis - By Country/ Sub-Region
    • 10.6.1. GCC Countries
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles
    • 11.5.1. Genentech, Inc.
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & Services,
      • 11.5.1.3. SWOT Analysis,
      • 11.5.1.4. Recent Developments,
      • 11.5.1.5. Strategies,
      • 11.5.1.6. Financials (Based On Availability)
    • 11.5.2. Shionogi & Co., Ltd.
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & Services,
      • 11.5.2.3. SWOT Analysis,
      • 11.5.2.4. Recent Developments,
      • 11.5.2.5. Strategies,
      • 11.5.2.6. Financials (Based On Availability)
    • 11.5.3. Seqirus (CSL)
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & Services,
      • 11.5.3.3. SWOT Analysis,
      • 11.5.3.4. Recent Developments,
      • 11.5.3.5. Strategies,
      • 11.5.3.6. Financials (Based On Availability)
    • 11.5.4. BIOCRYST PHARMACEUTICALS, INC.
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & Services,
      • 11.5.4.3. SWOT Analysis,
      • 11.5.4.4. Recent Developments,
      • 11.5.4.5. Strategies,
      • 11.5.4.6. Financials (Based On Availability)
    • 11.5.5. GlaxoSmithKline plc
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & Services,
      • 11.5.5.3. SWOT Analysis,
      • 11.5.5.4. Recent Developments,
      • 11.5.5.5. Strategies,
      • 11.5.5.6. Financials (Based On Availability)
    • 11.5.6. Lupin Limited
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & Services,
      • 11.5.6.3. SWOT Analysis,
      • 11.5.6.4. Recent Developments,
      • 11.5.6.5. Strategies,
      • 11.5.6.6. Financials (Based On Availability)
    • 11.5.7. Teva Pharmaceutical Industries Ltd.
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & Services,
      • 11.5.7.3. SWOT Analysis,
      • 11.5.7.4. Recent Developments,
      • 11.5.7.5. Strategies,
      • 11.5.7.6. Financials (Based On Availability)
    • 11.5.8. Zydus Pharmaceuticals, Inc. (Zydus Cadila)
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & Services,
      • 11.5.8.3. SWOT Analysis,
      • 11.5.8.4. Recent Developments,
      • 11.5.8.5. Strategies,
      • 11.5.8.6. Financials (Based On Availability)
    • 11.5.9. Amneal Pharmaceuticals LLC
      • 11.5.9.1. Overview,
      • 11.5.9.2. Products & Services,
      • 11.5.9.3. SWOT Analysis,
      • 11.5.9.4. Recent Developments,
      • 11.5.9.5. Strategies,
      • 11.5.9.6. Financials (Based On Availability)
    • 11.5.10. Macleods Pharmaceuticals Ltd.
      • 11.5.10.1. Overview,
      • 11.5.10.2. Products & Services,
      • 11.5.10.3. SWOT Analysis,
      • 11.5.10.4. Recent Developments,
      • 11.5.10.5. Strategies,
      • 11.5.10.6. Financials (Based On Availability)
    • 11.5.11. Alvogen
      • 11.5.11.1. Overview,
      • 11.5.11.2. Products & Services,
      • 11.5.11.3. SWOT Analysis,
      • 11.5.11.4. Recent Developments,
      • 11.5.11.5. Strategies,
      • 11.5.11.6. Financials (Based On Availability)
    • 11.5.12. Others
      • 11.5.12.1. Overview,
      • 11.5.12.2. Products & Services,
      • 11.5.12.3. SWOT Analysis,
      • 11.5.12.4. Recent Developments,
      • 11.5.12.5. Strategies,
      • 11.5.12.6. Financials (Based On Availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 2: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 3: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 6: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 7: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 8: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Influenza Medication Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 11: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 12: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 13: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 17: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 18: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 22: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 23: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 27: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 28: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Influenza Medication Market Revenue Breakdown (US$ Mn, %) by Region, 2025-2034
  • Figure 2: Global Influenza Medication Market Value Share (%), by Treatment, 2025-2034
  • Figure 3: Global Influenza Medication Market Forecast (US$ Mn), by Baloxavir marboxil, 2021-2034
  • Figure 4: Global Influenza Medication Market Forecast (US$ Mn), by Oseltamivir phosphate, 2021-2034
  • Figure 5: Global Influenza Medication Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 6: Global Influenza Medication Market Value Share (%), by Influenza Type, 2025-2034
  • Figure 7: Global Influenza Medication Market Forecast (US$ Mn), by Influenza A, 2021-2034
  • Figure 8: Global Influenza Medication Market Forecast (US$ Mn), by Influenza B, 2021-2034
  • Figure 9: Global Influenza Medication Market Value Share (%), by Route of Administration, 2025-2034
  • Figure 10: Global Influenza Medication Market Forecast (US$ Mn), by Oral, 2021-2034
  • Figure 11: Global Influenza Medication Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 12: Global Influenza Medication Market Value Share (%), by Distribution Channel, 2025-2034
  • Figure 13: Global Influenza Medication Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 14: Global Influenza Medication Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
  • Figure 15: Global Influenza Medication Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 16: Global Influenza Medication Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 17: Global Influenza Medication Market Value (US$ Mn), by Region, 2025-2034
  • Figure 18: North America Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 19: North America Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 20: North America Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 21: North America Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 22: North America Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 23: North America Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 24: North America Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 25: North America Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 26: North America Influenza Medication Market Value (US$ Mn), By Country, 2025-2034
  • Figure 27: North America Influenza Medication Market Value Share (%), By Country, 2025
  • Figure 28: Europe Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 29: Europe Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 30: Europe Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 31: Europe Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 32: Europe Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 33: Europe Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Europe Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 35: Europe Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Europe Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 37: Europe Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Asia Pacific Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 39: Asia Pacific Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 40: Asia Pacific Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 41: Asia Pacific Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 42: Asia Pacific Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 43: Asia Pacific Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 44: Asia Pacific Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 45: Asia Pacific Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 46: Asia Pacific Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 47: Asia Pacific Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 48: Latin America Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 49: Latin America Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 50: Latin America Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 51: Latin America Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 52: Latin America Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 53: Latin America Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 54: Latin America Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 55: Latin America Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 56: Latin America Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 57: Latin America Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 58: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 59: Middle East & Africa Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 60: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 61: Middle East & Africa Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 62: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 63: Middle East & Africa Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 64: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 65: Middle East & Africa Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 67: Middle East & Africa Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Influenza Medication Market Share (%), By Company, 2025